Neos Therapeutics Announces Issuance of New U.S. Methods of Use Patent for N-desethyloxybutynin
“We are very pleased to have secured this important method of use patent from the USPTO. The issuance of this patent further supports our efforts to explore the potential of NT0502 to treat sialorrhea in patients with neurological disorders, particularly Parkinson’s Disease, given the significant psychosocial and medical impact they experience,” said
NT0502 (N-desethyloxybutynin) is a new chemical entity being developed as an oral, once- or twice-daily treatment to reduce chronic sialorrhea in patients with neurological and other conditions associated with excess saliva and drooling. Based on preclinical data, the company believes that NT0502 offers the potential for an improved tolerability profile and an easier-to-dose oral formulation, without the need for complex titration, compared to existing treatment options. N-desethyloxybutynin is an active metabolite of oxybutynin, an approved drug to treat a urological condition.
Sialorrhea is defined as prevalent and excessive drooling from the mouth as a result of limitations in a person’s ability to control and swallow oral secretions1,2. Sialorrhea can lead to significant physical and psychosocial complications, including perioral chapping, aspiration, dehydration, infection, foul odor, stigmatization, and increased dependency and level of care, all of which can create an additional burden for these medically complicated patients1,3. In the
About Neos Therapeutics
Certain statements in this press release constitute “forward-looking statements” within the meaning of The Private Securities Litigation Reform Act of 1995. Forward-looking statements may involve statements about future expectations, plans and prospects for the Company, including statements about the Company’s strategy, future operations, commercial products, clinical development of its therapeutic candidates, plans for potential future product candidates, financial condition and outlook, intellectual property, and other statements containing the words “anticipate,” “believe,” “estimate,” “expect,” “intend,” “may,” “plan,” “predict,” “project,” “suggest,” “target,” “potential,” “will,” “would,” “could,” “should,” “continue,” and similar expressions, constitute forward-looking statements. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including: the impact of COVID-19, including with respect to the clinical development of NT0502; the status, timing, costs, results and interpretation of the Company’s clinical trials or any future trials, including whether the Company will initiate a Phase 1 ascending dose study of NT0502 in the second half of 2020; the uncertainties inherent in conducting clinical trials, including any potential impact on timing resulting from COVID-19; expectations for regulatory interactions, submissions and approvals; the financial condition and outlook for the Company; availability of funding sufficient for the Company’s foreseeable and unforeseeable operating expenses and capital expenditure requirements; uncertainties related to the Company’s intellectual property, including with respect to the
- Hockstein NG, et al. Sialorrhea: a management challenge. Am Fam Physician. 2004; 69: 2628-34.
- Chou KL, et al. Sialorrhea in Parkinson’s Disease: a review. Movement Disorders. 2007; 22(16): 2306-2313.
- Bavikatte G, et al. Management of drooling of saliva. Br J Med Practitioners. 2012; 5(1): a507.
- Marras C, et al. Prevalence of Parkinson’s disease across
North America. npjParkinson’s Disease. 2018; 4(21): 1-22.
- Kalf JG, et al. Prevalence and definition of drooling in Parkinson’s disease: a systematic review. J Neurol. 2009; 256: 1391-1396.
- Maenner MJ, et al. Prevalence of cerebral palsy and intellectual disability among children identified in two US National Surveys, 2011-2013. Ann Epidemiol. 2016; 26(3): 222-226.
- Reid SM, et al. Prevalence and predictors of drooling in 7- to 14-year-old children with cerebral palsy: a population study. Dev Med Child Neurol. 2012; 54: 1032-1036.
- Mozaffarian D, et al. Heart disease and stroke statistics – 2016 update. Circulation. 2016; 133: e38-e360.
- Cohen DL, et al. Post-stroke dysphagia: a review and design considerations for future trials. Int J Stroke. 2016; Jun:11(4): 399-411.
- Alhashemi HH. Dysphagia in severe traumatic brain injury. Neurosciences. 2010: 15(4): 231-236.
- Garuti G, et al. Sialorrhea in patients with ALS: current treatment options. Degenerative Neurol Neuromuscular Dis. 2019; 9: 19-26.
- McGrath J, et al. Schizophrenia: a concise overview of incidence, prevalence, and mortality. Epidemiol Rev. 2008; 20: 67-76.
- Maher S, et al. Clozapine-induced hypersalivation: an estimate of prevalence, severity, and impact on quality of life. Ther Adv Psychopharmacol. 2016; 6(3): 178-184.
Sage Strategic Marketing
Chief Financial Officer
Stern Investor Relations, Inc.
Source: Neos Therapeutics, Inc.